Ástralía - enska - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg (equivalent: salmeterol, qty 0.05 mg); fluticasone propionate, quantity: 0.5 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: ?patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids ?patients who are symptomatic on current inhaled corticosteroid therapy,for the symptomatic treatment of patients with severe copd (fev1 <50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone salmeterol ciphaler 500/50 is not indicated for the initiation of bronchodilator therapy in copd.

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica, s.a. - salmeterol xinafoato - excipientes: etanol anhidro - adrenÉrgicos, inhalatorios - agonistas selectivos de receptores beta-2 adrenérgicos - salmeterol

Frakkland - franska - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoire glaxosmithkline - salmétérol base - suspension - 25 microgrammes - composition pour une dose > salmétérol base : 25 microgrammes . sous forme de : xinafoate de salmétérol > propionate de fluticasone : 50 microgrammes - adrénergiques en association avec des corticoïdes ou d’autres médicaments à l’exclusion des anticholinergiques

Frakkland - franska - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoire glaxosmithkline - salmétérol - suspension - 25 microgrammes - composition pour une dose > salmétérol : 25 microgrammes . sous forme de : xinafoate de salmétérol > propionate de fluticasone : 125 microgrammes - adrénergiques en association avec des corticoïdes ou d’autres médicaments à l’exclusion des anticholinergiques

Frakkland - franska - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoire glaxosmithkline - salmétérol - suspension - 25 microgrammes - composition pour une dose > salmétérol : 25 microgrammes . sous forme de : xinafoate de salmétérol > propionate de fluticasone : 250 microgrammes - adrénergiques en association avec des corticoïdes ou d’autres médicaments à l’exclusion des anticholinergiques

Kanada - enska - Health Canada

pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 100mcg; 50mcg - fluticasone propionate 100mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals

Kanada - enska - Health Canada

pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 250mcg; 50mcg - fluticasone propionate 250mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals

Kanada - enska - Health Canada

pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 500mcg; 50mcg - fluticasone propionate 500mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

laboratórios azevedos - indústria farmacêutica, s.a. - fluticasona + salmeterol - pó para inalação em recipiente unidose - 100 µg/dose + 50 µg/dose - salmeterol, xinafoato 0.07264 mg/dose ; fluticasona, propionato 0.1 mg/dose - salmeterol and fluticasone - genérico - duração do tratamento: longa duração

Bandaríkin - enska - NLM (National Library of Medicine)

prasco laboratories - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u), salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - fluticasone propionate/salmeterol diskus is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. fluticasone propionate/salmeterol diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use fluticasone propionate/salmeterol diskus is not indicated for the relief of acute bronchospasm. fluticasone propionate/salmeterol diskus inhalation powder 250/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. fluticasone propionate/salmeterol diskus inhalation powder 250/50 mcg is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. fluticasone propionate/salmeterol diskus inhalation po